… Channick has received consulting and speaker fees and research grants from Actelion,
Gilead, Pfizer, and United Therapeutics. Dr. Delcroix has received fees for serving as investigator…

… Channick, Robert P. Frantz, Ekkehard Grünig, Zhi Cheng Jing, Olga Moiseeva, Ioana R. …
Conflict of interest: RN Channick reports grants and personal fees from Actelion and Bayer, …

… Channick has received consulting and speaker fees and research grants from Actelion,
Gilead, Pfizer, and United Therapeutics. Dr. Hassoun has received research grants from Actelion …

Background Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …

Background Current therapies for pulmonary arterial hypertension have been adopted on the
basis of short-term trials with exercise capacity as the primary end point. We assessed the …

The efficacy and safety of combining bosentan, an orally active dual endothelin receptor
antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of …

BACKGROUND: The incidence of pulmonary hypertension resulting from chronic thrombotic
occlusion of the pulmonary arteries is significantly underestimated. Although medical …

Rationale: Small, open-label studies suggest that combinations of existing therapies may be
effective for pulmonary arterial hypertension (PAH). Objective: To evaluate the safety and …

Objectives : This study assessed the efficacy and safety of inhaled treprostinil in pulmonary
arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil. …

This study evaluated long-term outcome of pulmonary thromboendarterectomy (PTE) in
patients with chronic thromboembolic pulmonary hypertension (CTEPH). Survival, functional …